• Targeted Delivery: BPM31510 is a CoQ10-lipid nanoparticle conjugate designed for intravenous administration to deliver therapeutic levels of CoQ10 directly to the mitochondria to effectuate supraphysiological levels. • Clinical Momentum: BPGbio recently presented encouraging preliminary clinical data from multiple compassionate use cases at various mitochondrial conferences globally and has engaged the FDA on an expedited development path. • AI-Driven Discovery: The therapeutic potential of BPM31510 was validated using BPGbio's proprietary NAi platform, which models patient biology to reveal new applications for mitochondrial-targeting agents.
• Targeted Delivery: BPM31510 is a CoQ10-lipid nanoparticle conjugate designed for intravenous administration to deliver therapeutic levels of CoQ10 directly to the mitochondria to effectuate supraphysiological levels. • Clinical Momentum: BPGbio recently presented encouraging preliminary clinical data from multiple compassionate use cases at various mitochondrial conferences globally and has engaged the FDA on an expedited development path. • AI-Driven Discovery: The therapeutic potential of BPM31510 was validated using BPGbio's proprietary NAi platform, which models patient biology to reveal new applications for mitochondrial-targeting agents.